Skip to Main Content

3,700

Views

15

CrossRef citations to date

0

Altmetric

Original Articles

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Murielle RousselInstitut Universitaire du Cancer de Toulouse-Oncopole and University Hospital, Toulouse, France; Correspondence[email protected]

http://orcid.org/0000-0002-4045-9428 View further author information

,

Benjamin HebraudInstitut Universitaire du Cancer de Toulouse-Oncopole and University Hospital, Toulouse, France; View further author information

,

Cyrille HulinCHU, Bordeaux, France; View further author information

,

Aurore PerrotCHU de Nancy, University of Lorraine, Nancy, France; View further author information

,

Denis CaillotHôpital du Bocage, CHU de Dijon, Dijon, France; View further author information

,

Anne-Marie StoppaHematologie clinique, Institut Paoli-Calmettes, Marseille, France; View further author information

,

Margaret MacroHôpital Côte de Nacre, CHU de Caen, Caen, France; View further author information

,

Martine EscoffreHematologie clinique, Institut Paoli-Calmettes, Marseille, France; View further author information

,

Bertrand ArnulfHôpital Saint-Louis, AP-HP, Paris, France; View further author information

,

Karim BelhadjCHU Henri Mondor, Créteil, France; View further author information

,

Lionel KarlinHématologie clinique, CHU de Lyon HCL – GH Sud, Pierre-Bénite, France; View further author information

,

Laurent GarderetHôpital Pitié Salpétriere Saint-Antoine, AP-HP, Paris, France; View further author information

,

Thierry FaconHôpital Claude Huriez, CHRU de Lille, Lille, France; View further author information

,

Shien GuoEvidera, Waltham, MA, USA; View further author information

,

Josh WengEvidera, Waltham, MA, USA;

http://orcid.org/0000-0002-4951-9298 View further author information

,

Sujith DhanasiriCelgene International, A Bristol-Myers Squibb Company, Boudry, Switzerland; View further author information

,

Xavier LeleuPoitiers University Hospital, Poitiers, France; View further author information

,

Philippe MoreauNantes University Hospital, Nantes, FranceView further author information

&

Michel AttalInstitut Universitaire du Cancer de Toulouse-Oncopole and University Hospital, Toulouse, France; View further author information